Eurofarma Laboratorios SA, founded in 1972 and headquartered in São Paulo, Brazil, is a prominent pharmaceutical company dedicated to developing, manufacturing, and marketing innovative medications aimed at enhancing health and well-being. The company offers a diverse range of products, including branded and generic pharmaceuticals, over-the-counter medications, and biological therapies.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| EURFBZ 10.23% 2031-03-18 BRLEurofarma Laboratorios SA | Brazil | 2031-03-18 | 10.230 | 14.56 |
| EURFBZ 11.05% 2027-11-15 BRLEurofarma Laboratorios SA | Brazil | 2027-11-15 | 11.050 | 15.44 |
| EURFBZ ZC 2029-03-28 BRLEurofarma Laboratorios SA | Brazil | 2029-03-28 | — | — |
| EURFBZ ZC 2029-05-15 BRLEurofarma Laboratorios SA | Brazil | 2029-05-15 | — | — |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Eurofarma has actively participated in the bond market, having first issued bonds in 2018 to support its expansion plans. Notably, in 2021, the company launched a significant issuance that raised BRL 1 billion, aimed at funding operational enhancements and acquisitions. As of October 2023, Eurofarma's bonds yield approximately 6% compared to an industry average of 5.5%, showcasing competitive returns for retail investors.